A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia

Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review

(2011) Yoshiyuki Kurata et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects

(2010) Gemma Matthys et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics of Eltrombopag in Healthy Subjects and Patients With Chronic Idiopathic Thrombocytopenic Purpura

(2010) Ekaterina Gibiansky et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

(2010) Gregory Cheng et al.   LANCET

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

(2009) James B Bussel et al.   LANCET

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD